User login
Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).
Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ2 4.468; P = .035) and higher 2-year RFS rate (62.9% and 37.8%).
Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).
Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.
Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9
Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).
Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ2 4.468; P = .035) and higher 2-year RFS rate (62.9% and 37.8%).
Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).
Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.
Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9
Key clinical point: Compared with radical surgery (RS) alone, RS combined with hyperthermic intraperitoneal chemotherapy (HIPEC) improves the relapse-free survival (RFS) in patients with locally advanced gastric cancer (LAGC).
Major finding: Patients receiving RS+HIPEC vs RS alone had a significantly longer median RFS (not reached vs 22.0 months; χ2 4.468; P = .035) and higher 2-year RFS rate (62.9% and 37.8%).
Study details: This retrospective study propensity score-matched patients with LAGC who received RS+HIPEC (n = 106) with those who received RS alone (n = 106).
Disclosures: This study was sponsored by the National Nature Science Foundation of China. The authors declared no conflicts of interest.
Source: Shen C et al. Comparative study of the efficacy and safety of radical surgery with or without hyperthermic intraperitoneal chemotherapy in locally advanced gastric cancer: A propensity score-matching analysis. Ann Surg Oncol. 2022 (Aug 8). Doi: 10.1245/s10434-022-12348-9